Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
Roche's R&D rethink hits 20% of molecules as cancer drugs axed
The culls are part of a broader refocusing that has removed 20% of new molecules from the pipeline in recent quarters.
Nick Paul Taylor
Apr 24, 2024 4:27am
Pfizer closes R&D unit that spawned $7.1B anti-TL1A med
Apr 17, 2024 7:00am
Roche picks up Prenosis' sepsis AI tool for distribution
Apr 12, 2024 2:55pm
Genentech axes $3B Adaptimmune cell therapy deal
Apr 12, 2024 11:22am
Roche, Lilly blood test for Alzheimer's expedited at FDA
Apr 11, 2024 11:06am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am